While Mesoblast Limited ACN 109 431 870 (Mesoblast) has endeavoured to ensure that all information provided on the Mesoblast website is accurate and up to date, Mesoblast is not liable for any error, omission, misrepresentation or misstatement relating to this information.

 

Last Share Price

3 March – Key Bone Repair Patent Granted in the United States

25 February - Mesoblast Half-Year Results

21 December - Mesoblast - National Electronic Media Coverage

26 February: RBS Equities Research - Mesoblast (Buy) 1H10 - Master Blasters

22 January - RBS Equities Research: Mesoblast - Analysis of MSB’s Opportunities

8 January - Southern Cross Equities Research: Mesoblast – The Stem Cell Opportunity

22 December - RBS Equities Research: Diabetes - An Expanding Portfolio

July 2009 - Chairman’s Letter

May 2009 - Chairman’s Letter

May 2008 - Issue Nine